• AstraZeneca’s drugs with potential in 2018 Shulin Yang
    February 12, 2018
    The pharmaceutical product sales of AstraZeneca declined by 5% in 2017, to which Onglyza, Symbicort, and Crestor, etc. could be said to have made “big contributions”.
PharmaSources Customer Service